French Company Gets FDA Breakthrough Status For Brain Device
Executive Summary
The US FDA has designated Carthera’s SonoCloud-9 as a breakthrough device. The French company’s ultrasound technology is designed to treat a wide range of brain diseases, including recurrent glioblastoma.
You may also be interested in...
CarThera Secures First VC Investment To Run Pivotal Study Of Glioblastoma Therapy
CarThera has secured its first financial round from institutional investors to launch a pivotal trial evaluating the company's Sonocloud ultrasound therapy for patients with recurrent glioblastoma.
Novel VR Treatment For Mental Illness Gets FDA Breakthrough
The US FDA has granted its breakthrough designation to a virtual reality therapy that recreates everyday scenarios for patients dealing with severe anxiety and schizophrenia.
Biden’s Biomedical Research Initiative Moves One Step Closer To Fruition
The US House of Representatives overwhelmingly passed legislation authorizing the creation of a federal health agency to advance biomedical research. The bill now goes to the Senate.